Accueil › Myélome multiple › Indiana › Indianapolis
Essais cliniques pour Myélome multiple à Indianapolis, IN
13 études pour Myélome multiple recherchent des participants dans et autour de Indianapolis (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 3
- Franciscan Health, Indianapolis
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Recrutement en coursPhase 4
- Indiana University, Indianapolis
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recrutement en coursPhase 2
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
Collection of Tissue Samples for Cancer Research
Recrutement en coursÉtude observationnelle
- Indiana University - Purdue, Indianapolis
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Recrutement en coursPhase 3
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Recrutement en coursPhase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Methodist Hospital, Indianapolis
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Recrutement en coursPhase 1
- Indiana University, Indianapolis
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Recrutement en coursPhase 2
- Indiana University Health, Indianapolis
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Franciscan St. Francis Health /ID# 280928, Indianapolis
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Recrutement en coursPhase 1
- Indiana University Health Simon Cancer Center, Indianapolis
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Recrutement en coursPhase 1/2
- Community Health Network, Indianapolis
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Recrutement en coursPhase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Saint Catherine Hospital, Indianapolis
The Indiana Myeloma Registry
Recrutement en coursÉtude observationnelle
- Indiana University Simon Cancer Center, Indianapolis
Essais pour Myélome multiple dans d'autres villes
- New York City, NY60 études
- Boston, MA42 études
- Atlanta, GA41 études
- Houston, TX38 études
- Durham, NC37 études
- Nashville, TN32 études
- Denver, CO27 études
- Rochester, MN24 études
- St. Louis, MO24 études
- Columbus, OH24 études
- Baldwin Park, CA23 études
- Chicago, IL22 études
Autres études à Indianapolis
- Cancer du poumon non à petites cellules32 études
- Cancer (tous types)24 études
- Insuffisance cardiaque23 études
- Cancer du sein20 études
- Obésité20 études
- Cancer métastatique19 études
- Cancer colorectal18 études
- Cancer de l'ovaire17 études
- Cancer du poumon16 études
- Maladie cardiovasculaire16 études
- Diabète de type 114 études
- Cancer de l'endomètre14 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.